

T. F. Hatchette, GSK: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant. Abbvie: Consultant, Speaker honorarium. **S. A. McNeil**, GSK: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant. Merck: Collaborator and Consultant, Contract clinical trials and Speaker honorarium. Novartis: Collaborator, Contract clinical trials. Sanofi Pasteur: Collaborator, Contract clinical trials.

2497. Acute Flaccid Paralysis: 17-Year's Active Epidemiological Surveillance in a Pediatric Hospital in Argentina

Angela Gentile, MD¹; Maria Del Valle Juarez, MD¹; Maria Florencia Lucion, MD¹; Cristina Lema, PhD²; Daniela Girard, Bq²; Maria Soledad Areso, MD¹; Solana Rapaport, MD¹ and Cecilia Freire, PhD²; ¹Epidemiology, Hospital de Niños "Ricardo Gutiérrez," Buenos Aires, Argentina, ²Neurovirology Laboratory, ANLIS Malbran, Buenos Aires, Argentina

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM

Background. Argentina, as the same of LATAM countries certifies the elimination of polio in 1990. Acute flaccid paralysis (AFP) surveillance is a key strategy for monitoring the progress of poliomyelitis eradication in the world. The aim of this study was to describe the epidemiological pattern of patients reported with AFP.

Methods. A cross-sectional study was carried out from January 2000 to December 2016 at the "R. Gutierrez" Children's Hospital. All children aged <15 years who met the WHO definition for AFP were included. Stool samples were sent to the national reference laboratory to be tested for enteroviruses (non-polio enterovirus, poliovirus, Sabin, Sabin-derived) in compliance with the AFP protocol.

Results. A total of 174 cases were included; median age 62 months (IQR: 29–108); 53.5% males. No seasonality pattern was observed; 137(79%) stool samples were tested and no wild poliovirus was isolated. The median time between the onset of the paralysis and the admission was 4 days (IQR 2–9); the most common prodromal symptoms were: fever(39%),respiratory infection (35%), digestive (31%), myalgia (34%) and meningeal (5%). Symmetric paralysis (78%) without progression was the most frequent clinical presentation. The median length of stay at the hospital was 9 days (IQR 1-17). None of the patients was diagnosed as having polio vaccine related paralysis. Guillain-Barre syndrome was the most frequent final diagnosis (*n* = 72) followed by transverse myelitis (*n* = 14), botulism (*n* = 12) and encephalitis (*n* = 6). Between years 2000 and 2016 a total of eight cases of non-polio enterovirus (NPEV) were found: 6 cases of acute myelitis (AFM) associated to D68 enterovirus, clustered in winter 2016. Five of them were detected by PCR in nasopharyngeal aspirates and only one in stool samples. All of them present motor sequel.

Conclusion. Epidemiological surveillance of AFP allows ruling out poliovirus infection and detect other flaccid paralysis etiologies. In 2016 D-68 enterovirus AFM outbreak was detected in Argentina when conducting AFP routine surveillance. Nasopharyngeal aspirates, in AFM suspected cases, must be part of the study AFP protocol.

Disclosures. All authors: No reported disclosures.

2498. Association of Increasing Age With Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—US Influenza Hospitalization Surveillance Network (FluSurv-NET)

Christopher Czaja, MD MPH^{1,2}; Lisa Miller, MD, MSPH³; Nisha Alden, MPH²; Heidi Wald, MD, MSPH⁴; Charisse Nitura Cummings, MPH⁵; Melissa Rolfes, PhD, MPH⁵; Shikha Garg, MD, MPH⁵; Evan J. Anderson, MD^{6,7}; Nancy M. Bennett, MD, MS⁸; Laurie Billing, MPH²; Shua J. Chai, MD MPH¹⁰; Seth Eckel, MPH¹¹; Robert Mansmann, MPH¹²; Melissa McMahon, MPH¹³; Maya Monroe, MPH¹⁴; Alison Muse, MPH¹⁵; Ilene Risk, MPA¹⁶; William Schaffner, MD, FIDSA, FSHEA¹⁷; Ann Thomas, MD, MPH¹⁸; Kimberly Yousey-Hindes, MPH, CPH¹⁹ and Rachel Herlihy, MD MPH²; ¹Epidemiology, Colorado School of Public Health, Aurora, Colorado, ²Colorado Department of Public Health and Environment, Denver, Colorado, ³Preventive Medicine Residency Program, University of Colorado School of Public Health, Aurora, Colorado, ⁴SCL Health, Broomfield, Colorado, ⁵Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, ⁶Georgia Emerging Infections Program (EIP), Atlanta, Georgia, ⁷Pediatrics and Medicine, Emory University School of Medicine, Atlanta, Georgia, ⁸University of Rochester School of Medicine and Dentistry, Rochester, New York, ⁹Ohio Department of Health, Columbus, Ohio, ¹⁰California Department of Public Health, Oakland, California, ¹¹Communicable Disease Division, Michigan Department of Health and Human Services, Lansing, Michigan, ¹²New Mexico Emerging Infections Program, Albuquerque, New Mexico, ¹³Minnesota Department of Health, St. Paul, Minnesota, ¹⁴Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, ¹⁵New York State Department of Health, Albany, New York, ¹⁶Salt Lake County Health Department, Salt Lake City, Utah, ¹⁷Vanderbilt University School of Medicine, Nashville, Tennessee, ¹⁸Oregon Public Health Division, Portland, Oregon, ¹⁹Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM


Background. Few data describe the epidemiology of influenza among adults ≥65 years old according to age strata. We evaluated age-related differences in influenza-associated hospitalization rates, clinical presentation, and outcomes among older

adults at 14 FluSurv-NET sites during the 2011–2012 through 2014–2015 influenza seasons.

Methods. Study patients were hospitalized ≤14 days after and ≤3 days before a positive influenza test. Age strata were 65–74, 75–84, and ≥85 years old. We adjusted hospitalization rates for under detection and assessed for age-related trends in risk factors and symptoms. We used logistic regression to calculate odds ratios (OR) for pneumonia and in-hospital death adjusted for season, sex, nursing home residence, smoking, medical comorbidities, influenza vaccination, and study site.

Results. There were 19,760 patients, including 5,956 aged 65–74 years, 6,998 aged 75–84 years, and 6,806 aged ≥85 years. There was a stepwise increase in hospitalization rates with age (figure). Increasing age was positively associated with female sex, nursing home residence, neurologic disorder, cardiovascular and renal disease, and vaccination, and inversely associated with morbid obesity, smoking, asthma, chronic metabolic disease, and immunosuppression (*P* < 0.01). Among 10,548 (53.3%) patients with symptom data from 2014 to 2015, increasing age was associated with a higher prevalence of altered mental status and lower prevalence of fever, myalgias, respiratory or gastrointestinal symptoms, and headache (*P* ≤ 0.01). Compared with 65–74 year olds, older patients had a higher risk of pneumonia (≥85 year-olds: OR 1.2, 95% CI 1.0, 1.3, *P* = 0.01) and death (75–84 year olds: OR 1.4, 95% CI 1.2, 1.7, *P* < 0.01; ≥85 year-olds: OR 2.1, 95% CI 1.7, 2.6, *P* < 0.01).

Conclusion. There are age-related differences in the epidemiology, clinical presentation, and outcomes of older adults hospitalized with influenza. These may reflect differences in health status and healthcare provider practice patterns. Public health epidemiologists should consider using additional age strata in ≥65 year-olds when analyzing influenza surveillance data. Clinicians should be aware that influenza among the oldest adults may present atypically and that mortality is increased.



Disclosures. E. J. Anderson, NovaVax: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant. AbbVie: Consultant, Consulting fee. MedImmune: Investigator, Research support. PaxVax: Investigator, Research support. Micron: Investigator, Research support. W. Schaffner, Merck: Member, Data Safety Monitoring Board, Consulting fee. Pfizer: Member, Data Safety Monitoring Board, Consulting fee. Dynavax: Consultant, Consulting fee. Seqirus: Consultant, Consulting fee. SutroVax: Consultant, Consulting fee. Shionogi: Consultant, Consulting fee.

2499. Burden of Influenza Like Illness (ILI) Among Congregate Military Populations

Christian Coles, PhD^{1,2}; Wei-Ju Chen, PhD^{1,2}; Jacqueline Owens Milzman, MS^{1,2}; Scott Robinson, MD³; Carol Jones, BS^{1,2}; Nicole Moreno, BS^{1,2} and Timothy Burgess, MD, MPH¹; ¹Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, ²Henry M. Jackson Foundation, Bethesda, Maryland, ³Martin Army Community Hospital, Fort Benning, Georgia

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM

Background. Influenza-like illnesses (ILI) have placed a significant health burden on the United States Armed Forces for decades. Up to 300,000–400,000 of new cases of ILI result in clinical encounters in the US military annually. In congregate populations such as trainees, the impact is far greater due to crowding and stressors such as physical stress from training. Clinic-based surveillance may under-estimate the true ILI burden because trainees with ILI may not seek healthcare for fear of missing training, facilitating the spread of respiratory pathogens. To uncover the true ILI burden we estimated the attack rate of ILI in trainees irrespective of whether they sought care.

Methods. A prospective cohort study was conducted among US Army recruits in a 9-week basic combat training course at Ft. Benning, GA, in January–March 2017. Symptom diary cards were available to the trainees to record each day whether they had fever/chills/feverish feeling, cough, and/or sore throat, the symptoms of ILI. Attack rate was calculated as number of trainees with ILI divided by number of participants in the study.

Results. A total of 78 recruits participated in the study. The participants were male and the mean age was 21 years (SD 4.9). In the first two weeks of training, nine recruits reported to outpatient clinics for their ILI, resulting in an attack rate of 12%. Fifty-five recruits returned symptom diary cards with at least 13 days of records between visit 1 and visit 2. Among them, four trainees visited clinics for ILI while additional 14 trainees reported at least one day of ILI without seeking healthcare. The proportion of patients not seeking care was 78%. The attack rate of self-reported ILI (to health clinics or on symptom cards) was 33% (18/55). The self-reported ILI participants reported a median of 2 days of having ILI (range: 1–7 days).

Conclusion. Our data showed that the majority of trainees reporting ILI did not seek healthcare. The attack rate based on clinic attendance largely underestimated the ILI burden. Understanding reasons and obstacles of trainees not seeking care would be crucial in infection control and reduction of ILI transmission among basic training recruits who are at high risk of ILI.

Disclosures. All authors: No reported disclosures.

2500. Incidence of Herpes Zoster in the Pre- and Post-Vaccine Era: Do Trends Differ Between Blacks And Whites?

Kathleen Dooling, MD, MPH¹; John Zhang, PhD²; Angela Guo, MPH³; Susannah McKay, PhD, MPH⁴ and Rafael Harpaz, MD¹; ¹DVD, Centers for Disease Control and Prevention, Atlanta, Georgia, ²Centers for Disease Control and Prevention, Atlanta, Georgia, ³Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, ⁴Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM

Background. Herpes zoster (HZ) incidence in blacks is 25%–65% lower than in whites in the United States. Since 2007 and the widespread introduction of Zostavax (ZVL), studies report plateauing or decreasing HZ incidence in the United States among persons ≥60 years. We examined HZ incidence and ZVL coverage trends by race among Medicare beneficiaries, in the pre- and post-vaccine era.

Methods. We used administrative health claims from a 5% sample of Medicare beneficiaries ≥65 years. We defined incident cases as HZ in the first diagnostic position, with no HZ code in the previous year, among beneficiaries enrolled in Part A and B, from 1992 to 2015. We calculated incidence of first HZ episode by dividing the number of cases by the total number of person-years (p-y). A case was a censoring event. We used Poisson regression to compare HZ incidence by race before and after 2007. We calculated vaccine coverage by dividing the total number of persons with ZVL in Medicare Part D by the number of eligible enrollees.

Results. We identified 266,745 first HZ episodes. Prior to 2007, HZ incidence increased among both blacks and whites. Although incidence was double in whites vs. blacks (10.3 vs. 5.0 cases/1000 p-y), the rate of increase was similar ($P = 0.75$). From introduction of ZVL to 2015, HZ incidence decreased 1.8%/year in whites and did not change significantly in blacks ($P < 0.001$) (figure). By 2015, ZVL uptake in Medicare among blacks was less than half that among whites (7.3% vs. 19.9%).

Conclusion. Incidence of HZ increased at a similar rate for black and white Medicare beneficiaries in the pre-vaccine era. In the post-vaccine era, incidence has decreased among whites and plateaued among blacks. Though the reasons for racial difference and temporal changes in HZ incidence remain unknown, ecologic association suggests higher vaccination rates may contribute to steeper HZ declines among whites in the post vaccine era.

Disclosures. All authors: No reported disclosures.

2501. Impact of Influenza A and B Infection on Stem Cell Transplant Patients During the 2017–2018 Season at a Single Center

Khin Sandar Pyai, MD¹; Stephen G. Jenkins, PhD²; Tsiporah B. Shore, MD³; Koen Van Besien, MD, PhD²; Michael J. Satlin, MD, MS⁴; Lars F. Westblade, PhD⁵; Rosemary Soave, MD, FIDSA² and Mirella Salvatore, MD⁶; ¹Weill Cornell Medical College, New York, New York, ²NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, ³Weill Cornell Medical Center/ New York Presbyterian Hospital, New York, New York, ⁴Weill Cornell Medicine of Cornell University, New York, New York, ⁵NewYork-Presbyterian Hospital, New York, New York, ⁶Medicine, Weill Cornell Medical College, New York, New York

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM

Background. Seasonal influenza causes significant morbidity and mortality on HSCT recipient. The 2017–2018 influenza has been characterized in the United States by prolonged high rates of both influenza A (IAV) and B (IBV) and low vaccine effectiveness. The aim of this study was to assess the impact of both IAV and IBV during 2017–2018 influenza season on a cohort of stem cell transplant (SCT) recipients at Weill Cornell- NYP.

Methods. We reviewed charts of HSCT recipients that were diagnosed with influenza by PCR on nasopharyngeal swabs. Demographics, clinical and microbiological data, and outcomes were collected. The study was approved by Weill Cornell Institutional review board.

Results. From September 2017 to March 2018, 30 stem cell transplant recipient at NYP were diagnosed with influenza. IAV cases peaked in January (11 cases) while IBV infected-patients were equally distributed from December to March. Infected subject were more likely to be male ($n = 20, 66.6\%$) with mean age of 57 ± 12 (IAV) vs. 59 ± 11

(IBV). Nine patients had received auto SCT and 21 patient allo SCT. Most common symptoms were cough (present in all patients), fever (28/30), nausea, dyspnea. Patient received oseltamivir (for 5 or 10 days) in 28/30 cases, with one patient developing resistance under treatment. Interestingly both IAV and IBV caused lower respiratory tract infection (LRTI, 7 cases) with severe pneumonia (IAV 1 cases, IBV 2 cases) and intubation. In two severe cases IV was detected in the BAL. 13 subjects (56%) with a URTI and 4 (43%) subjects with LRTI had not received the influenza vaccine for the season. Prolonged shedding of influenza on oseltamivir treatment was documented in 7 patients.

Conclusion. Both IAV and IBV are serious threat in SCT population. Vaccination and oseltamivir are useful tools. Resistance testing should be considered in subjects with prolonged disease.

Disclosures. S. G. Jenkins, Merck: Grant Investigator, Grant recipient. M. J. Satlin, Hardy Diagnostics: Grant Investigator, Research support. Allergan: Grant Investigator, Grant recipient. Merck: Grant Investigator, Grant recipient. Biomerieux: Grant Investigator, Grant recipient. Achaogen: Consultant, Consulting fee. L. F. Westblade, Accelerate Diagnostics: Grant Investigator, Grant recipient. Biomerieux: Grant Investigator, Grant recipient. Allergan: Grant Investigator, Grant recipient. Merck: Grant Investigator, Grant recipient.

2502. Host Susceptibility to Andes Hantavirus Infection Associates to a Single Nucleotide Polymorphism at the $\alpha V\beta 3$ Integrin

Constanza Martinez-Valdebenito, MSc¹; Marcela Ferres, MD, MPH²; Nicole Le Corre, MD/PhD³; Jennifer Angulo, PhD¹; Cecilia Vial, PhD³; Pablo Vial, MD⁴; Gregory Mertz, MD, FIDSA⁵; Francisca Valdivieso, MD⁶; Hector Galeno, MSc⁷; Eliecer Villagra, TM⁸; Lilian Vera, MD⁷; Natalia Lagos, TM⁸; Natalia Becerra, TM³; Judith Mora, MD⁸ and Marcelo Lopez-Lastra, PhD¹; ¹Dpto Infectologia e Inmunologia Pediatrica, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Dpto De Enfermedades Infecciosas e Inmunologia Pediatrica, Pontificia Universidad Católica de Chile, Santiago, Chile, ³Center for Genetics and Genomics, Universidad del Desarrollo, Santiago, Chile, ⁴Pediatrics, University Del Desarrollo, Santiago, Chile, ⁵Internal Medicine, University of New Mexico, Albuquerque, New Mexico, ⁶Universidad del Desarrollo, Santiago, Chile, ⁷Subdepartamento De Virologia Clínica, Departamento Laboratorio Biomédico Nacional y De Referencia, Instituto de Salud Publica, Santiago, Chile, ⁸Subdepartamento De Virologia Clínica, Departamento Laboratorio Biomédico Nacional y De Referencia, Instituto de Salud Publica, Santiago, Chile

Session: 255. Virology Potpourri
Saturday, October 6, 2018: 12:30 PM

Background. ANDV is etiologic agent of hantavirus cardiopulmonary syndrome (HCPS) in Chile. Transmission occurs mainly by exposure to aerosolized excretes of infected rodents, person-to-person transmission has also been reported. ANDV infected endothelial cell through $\alpha V\beta 3$ integrin at plexin-semaphorin-integrin (PSI) domain. *In vitro* assays establish that the change from leucine to proline, at residues 33 in PSI-domain inhibits ANDV recognition of integrin. Here we assessed the risk that represents a polymorphism leucine to proline (L33P) and the association to susceptibility to ANDV.

Methods. For risk assessment, 74 cases and 105 controls (exposed but not infected) were genotyped by Taqman assay, epidemiological and demographic data were recorded. We also evaluated SNP distribution at general population, infected population (serum collection) and 11 prospectively diagnosed ANDV cases. A regression logistic model was used to assess environmental or person to person risks factors of hantavirus infection either in presence or absence of the “susceptible” or “protective” genotypes.

Results. In cases and controls the susceptible (TT) genotype (Leucine) was distributed in an 89.2 and 60%, respectively (Figure 1). The protective genotype (CC) was absent among cases but present at 11.4% in exposed controls. We estimated the Odds ratio (OR), through a logistic model, first using only previously described risk activities and after adding the genotype TT; the OR increased from 6.2 to 12.6. Cases and control at same exposure (access to abandoned place) showed that controls have a 57% of TT genotype, meanwhile in cases was 91%, with an OR of 7.3. For a second common exposure activities (handle woods) the controls had a 59.4% of TT genotype, meanwhile for cases 85%. For general and infected population both did not show statistical differences in allele distribution, and we detected a 1.7% of CC genotype in the infected population (Figure 2). We did not detected CC genotypes in the eleven prospective ANDV cases.

Conclusion. There was association between this particular SNP and infection susceptibility to ANDV. We highlight the relevance of genetic background in host-virus interaction. Nevertheless, other factors such as innate immune system or viral variability must be explored to fully understand the disease pathogenesis.

Disclosures. C. Martinez-Valdebenito, FONDECYT1161197: Grant Investigator, Educational grant. ACT1408: Grant Investigator, Research grant. M. Ferres, FONDECYT1161197: Grant Investigator, Research grant. ACT1408: Grant Investigator, Research grant. N. Le Corre, FONDECYT1161197: Grant Investigator, Research grant. ACT1408: Grant Investigator, Research grant. J. Angulo, FONDECYT1161197: Grant Investigator, Research grant. ACT1408: Grant Investigator, Research grant.

2503. Assessment of State-Level Influenza Season Severity—Utah, 2017–2018

Michelle M. Hughes, PhD, MHS¹; Anna Carmack, MD, MPH²; Gregg M. Reed, MPH³; Melanie Spencer, MPH⁴; Shikha Garg, MD, MPH¹; Angela Dunn, MD, MPH³